Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: Results of the enoxaparin versus tinzaparin (EVET) trial at 6 months

American Heart Journal

Volumn 150, Issue 3, 2005, Pages 385-391

  Katsouras, Christos ^a   Michalis, Lampros K ^a,b   Papamichael, Nikos ^a   Adamides, Kostas ^a   Naka, Katerina K ^a   Nikas, Dimitris ^a   Goudevenos, John A ^a   Sideris, Dimitris A ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; TINZAPARIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR PROCEDURES; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANGINA, UNSTABLE; ELECTROCARDIOGRAPHY; ENOXAPARIN; FEMALE; FOLLOW-UP STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SYNDROME; TIME FACTORS;

EID: 24944519320     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.09.028     Document Type: Article

References (27)

1. V. Fuster, L. Badimon, and J.J. Badimon The pathogenesis of coronary artery disease and the acute coronary syndromes (2) N Engl J Med 326 1992 310 318
2. E. Braunwald, R.H. Jones, and D.B. Mark Diagnosing and managing unstable angina: Agency for Health Care Policy and Research Circulation 90 1994 613 622
3. J. Hirsh, and M.N. Levine Low molecular weight heparin Blood 79 1992 1 17
4. T.E. Warkentin, M.N. Levine, and J. Hirsh Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin N Engl J Med 332 1995 1330 1335
5. S.A. Spinler, and J.J. Nawarskas Low-molecular-weight heparins for acute coronary syndromes Ann Pharmacother 32 1998 103 110
6. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group Low-molecular-weight heparin during instability in coronary artery disease Lancet 347 1996 561 568
7. W. Klein, A. Buchwald, and S.E. Hillis Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease (FRIC) Circulation 96 1997 61 68
8. The Frax.I.S Study Group Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome) Eur. Heart. J. 20 1999 1553 1562
9. T.T. Suvarna, J.A. Parikh, and R. Keshav Comparison of clinical outcome of fixed-dose subcutaneous low molecular weight heparin (tinzaparin) with conventional heparin in unstable angina: a pilot study Indian Heart J. 49 1997 159 162
10. M. Cohen, C. Demers, and E.P. Gurfinkel A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events Study Group N. Engl. J. Med. 337 1997 447 452
11. E.M. Antman, C.H. McCabe, and E.P. Gurfinkel Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial Circulation 100 1999 1593 1601
12. E.P. Gurfinkel, E.J. Manos, and R.I. Mejail Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia J. Am. Coll. Cardiol. 26 1995 313 318
13. J.W. Eikelboom, S.S. Anand, and K. Malmberg Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis Lancet 355 2000 1936 1942
14. A. Oler, M.A. Whooley, and J. Oler Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis JAMA 276 1996 811 815
15. S.G. Goodman, M. Cohen, and F. Bigonzi Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events J. Am. Coll. Cardiol. 36 2000 693 698
16. E.M. Antman, M. Cohen, and C. McCabe TIMI 11B and ESSENCE Investigators. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE Eur. Heart J. 23 2002 308 314
17. L.K. Michalis, C.S. Katsouras, and N. Papamichael Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial Am. Heart J. 146 2003 304 310
18. R.D. Hull, G.E. Raskob, and G.F. Pineo Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis N. Engl. J. Med. 326 1992 975 982
19. G. Simonneau, H. Sors, and B. Charbonnier A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group N. Engl. J. Med. 337 1997 663 669
20. E. Van Belle, J.M. Lablanche, and C. Bauters Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis Circulation 97 1998 26 33
21. P.A. Merlini, K.A. Bauer, and L. Oltrona Persistent activation of coagulation mechanism in unstable angina and myocardial infarction Circulation 90 1994 61 68
22. M. Ernofsson, F. Strekerud, and H. Toss Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease Thromb. Haemost. 79 1998 491 494
23. J. Fareed, W. Jeske, and D. Hoppensteadt Low-molecular-weight heparins: pharmacologic profile and product differentiation Am. J. Cardiol. 82 1998 3L 10L
24. J.S. Barrett, J.W. Hainer, and D.M. Kornhauser Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers Thromb. Res. 101 2001 243 254
25. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A J. Am. Coll. Cardiol. 29 1997 1474 1482
26. G. Montalescot, F. Philippe, and A. Ankri Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Beneficial effects of enoxaparin Circulation 98 1998 294 299
27. G. Montalescot, J.P. Collet, and R. Choussat A rise of troponin and/or von Willebrand factor over the first 48h is associated with a poorer 1-year outcome in unstable angina patients Int. J. Cardiol. 72 2000 293 294